Back
Podium Abstract
Eposter Presentation
 
Accept format: PDF. The file size should not be more than 5MB
 
Accept format: PNG/JPG/WEBP. The file size should not be more than 2MB
 
Submitted
Abstract
Diagnostic Accuracy of 68Ga-PSMA PET/CT to Identify Residual Prostate Cancer Following Focal Therapy with Irreversible Electroporation for Localised Prostate Cancer: A Prospective Study
Podium Abstract
Clinical Research
Oncology: Prostate
Author's Information
6
No more than 10 authors can be listed (as per the Good Publication Practice (GPP) Guidelines).
Please ensure the authors are listed in the right order.
Australia
Daniel Feng d.feng1996@gmail.com St. Vincent’s Private Hospital (St. Vincent’s Prostate Cancer Research Centre) Sydney Australia *
Isabella Williams d.feng1996@gmail.com St. Vincent’s Private Hospital (St. Vincent’s Prostate Cancer Research Centre) Sydney Australia -
Louise Emmett d.feng1996@gmail.com St. Vincent’s Hospital, Sydney Sydney Australia -
Shikha Agrawal d.feng1996@gmail.com St. Vincent’s Private Hospital (St. Vincent’s Prostate Cancer Research Centre) Sydney Australia -
James Thompson d.feng1996@gmail.com St. Vincent’s Private Hospital (St. Vincent’s Prostate Cancer Research Centre) Sydney Australia -
Phillip Stricker d.feng1996@gmail.com St. Vincent’s Private Hospital (St. Vincent’s Prostate Cancer Research Centre) Sydney Australia -
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abstract Content
Currently the follow up of prostate cancer following primary focal therapy with irreversible electroporation involves serial PSA, and an MRI at 6 months, and repeat prostate biopsy at 12 months. Due to scarring post IRE, MRI can be difficult to interpret, particularly for radiologists in centres with low volumes of focal therapy. This study aims to establish the diagnostic accuracy of PSMA PET/CT in detecting residual/recurrent clinically significant PCa at 12 months post focal IRE, defined as ISUP grade group 2-5 (with >1mm of pattern 4 present).
This is a prospective single site study. All male patients over the age of 18 undergoing primary focal IRE (Nanoknife®) for prostate cancer were sequentially recruited, and underwent a PSMA PET/CT 9-12 months post IRE (Nanoknife®) which will be double read by St Vincent’s Hospital Theranostic and Nuclear Medicine department in addition to current best practice; an MRI at 6-12 months post IRE procedure and a Transperineal systematic template biopsy at 12-18 months post IRE. The accuracy of the PSMA PET/CT was then calculated using the biopsy as the gold standard.
The calculated sample size was 154 patients. Due to slow recruitment and cost, an interim analysis was carried after 19 patients were recruited. At the 1 year biopsy, 7 patients had no recurrence of prostate cancer, 6 patients had clinically insignificant ISUP 1 disease, and 6 patients had clinically significant disease ISUP 2 or greater, with a calculated incidence of 31.5%. In our full series of primary IRE cases, the calculated incidence of clinically significant recurrence was 23.1%. When corrected, the sensitivity was 50% (95% CI 11.81% to 88.19%), the specificity was 38.46% (8=95% CI 13.86% to 68.42%), and the NPV was 71.92% (95% CI 47.14% to 88.03%).
PSMA PET/CT had a low sensitivity and specificity for detecting prostate cancer recurrence or residual disease at 1 year post IRE for prostate cancer. The poor negative predictive value means that a template prostate biopsy is necessary in the follow up of IRE patients.
PSMA PET, IRE, focal therapy, prostate cancer
 
 
 
 
 
 
 
 
 
 
1788
 
Presentation Details
Free Paper Podium(25): Oncology Prostate (F)
Aug. 17 (Sun.)
13:36 - 13:42
2